Specialty hub

Haematology

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Haematology.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Haematology is the branch of medicine that deals with disorders or abnormalities in the blood and connected areas such as blood cells, haemoglobin and blood vessels. Haematology also covers bone marrow and spleen, which are the blood producing organs.

Featured Learning Zones

Learning Zone Homepage

Fibrinogen Deficiency in Bleeding Learning Zone

Fibrinogen is an essential coagulation factor in the blood clotting cascade. The importance for fibrinogen in normal haemostasis is highlighted in patients of inherited fibrinogen deficiencies who display coagulopathies such as excessive bleeding and thrombolytic events.

Learning Zone Homepage

Oral Anticoagulation Reversal Learning Zone

This educational resource is designed to help healthcare professionals diagnose, manage and treat bleeding in patients taking anticoagulants.

Venous Thromboembolism (VTE) Learning Zone

Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE), and is associated with long-term complications, disability and significant mortality.

Learn more

Haematology focuses on the study, diagnosis, treatment, and prevention of diseases including coagulation and haemorrhagic disorders such as fibrinogen deficiency, haematological and bone marrow cancers such as leukaemia and lymphoma, and anaemia.

Diseases in this section

Coagulation and Haemorrhagic Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Haematological and Bone Marrow Cancers

Containing relevant Learning Zones, guidelines, trials and news.

HIV

Containing relevant Learning Zones, guidelines, trials and news.

Venous thromboembolism

Containing relevant Learning Zones, guidelines, trials and news.

Related news and insights

Drug news

European Commission approves label expansion of Hemlibra to include people with moderate haemophilia A in the EU

Roche announced that the European Commission approved the expansion of the Hemlibra (emicizumab) European Union (EU) marketing authorisation. The label will now include the routine prophylaxis of bleeding episodes in people with haemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, who have moderate disease (FVIII greater than 1% and less than 5%) with a severe bleeding phenotype. Haemophilia A affects around 900,000 people worldwide, approximately 14% of whom have a moderate form of the disease

1 mins

Drug news

Phase III CARTITUDE-4 study of Carvykti meets primary endpoint in multiple myeloma.- Legend Biotech Corp

Legend Biotech Corp announced that CARTITUDE-4, the Phase III study evaluating Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint of showing a statistically significant improvement in progression-free survival (PFS) compared to standard therapy at the study’s first pre-specified interim analysis.

1 min

Drug news

FDA approves Jaypirca , the first and only non-covalent (reversible) BTK inhibitor, for adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor.- Loxo@Lilly/Eli Lilly.

Loxo@Lilly, the oncology unit of Eli Lilly and Company announced that the FDA approved Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.

2 min

See all news

Related Drugs

FDA Hero Banner - Multi-coloured pills and tablets

Bortezomib BORTEZOMIB 3.5 mg/1 Ingenus Pharmaceuticals, LLC

11 mins

Warfarin Sodium WARFARIN SODIUM 5 mg/1 PD-Rx Pharmaceuticals, Inc.

7 mins

VYTORIN EZETIMIBE 10 mg/1 Organon LLC

3 mins

VYTORIN EZETIMIBE 10 mg/1 Organon LLC

3 mins

Heparin Sodium HEPARIN SODIUM 1000 [USP'U]/mL Meitheal Pharmaceuticals Inc.

5 mins

Warfarin Sodium WARFARIN SODIUM 6 mg/1 REMEDYREPACK INC.

7 mins

Desmopressin Acetate DESMOPRESSIN ACETATE 4 ug/mL Amring Pharmaceuticals Inc.

3 mins

Lenalidomide LENALIDOMIDE 10 mg/1 Mylan Pharmaceuticals Inc.

9 mins

Desmopressin Acetate DESMOPRESSIN ACETATE 4 ug/mL Sun Pharmaceutical Industries, Inc.

3 mins

Calcium acetate CALCIUM ACETATE 667 mg/1 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

1 mins

Deferasirox DEFERASIROX 180 mg/1 Northstar Rx LLC.

9 mins

Deferasirox DEFERASIROX 360 mg/1 Northstar Rx LLC.

9 mins

Deferasirox DEFERASIROX 90 mg/1 Northstar Rx LLC.

9 mins

DEFERASIROX DEFERASIROX 500 mg/1 Zydus Lifesciences Limited

1 mins

Heparin Sodium HEPARIN SODIUM 10000 [USP'U]/100mL Fresenius Kabi USA, LLC

4 mins

Related Journals

Journal

Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report

2 mins

Journal

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

2 mins

Journal

Distinct viral reservoirs in individuals with spontaneous control of HIV-1

1 mins

Journal

Recent Advances in the Development of Integrase Inhibitors for HIV Treatment

1 mins

Journal

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

1 mins

Journal

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

1 mins

Journal

Advances toward Curing HIV-1 Infection in Tissue Reservoirs

1 mins

Journal

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety

1 mins

Journal

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

1 mins

Journal

Dolutegravir plus lamivudine for the treatment of HIV-1 infection

1 mins

Related Guidelines

Guideline

BHIVA guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update)

The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of women living with HIV in the UK during pregnancy and postpartum, and their infants.

1 mins

Guideline

British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019

The aim of the opportunistic infection guidelines is to help physicians investigate and manage people living with HIV with, or suspected of having, an opportunistic infection. They are primarily intended to guide practice in the UK and related healthcare systems.

1 min

Guideline

British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of gastrointestinal opportunistic infections 2020

Gastrointestinal (GI) symptoms occur frequently in people living with HIV. Dysphagia and diarrhoea may be caused by a wide variety of infections.

1 min

See all guidelines